Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
Magdalena Madero, Adeera Levin, Sofia B. Ahmed, Juan Jesús Carrero, Bethany J. Foster, Anna Francis, Rasheeda K. Hall, William G. Herrington, G. Hill, Lesley A. Inker, Rümeyza Kazancıoğlu, Edmund J. Lamb, Peter Lin, Natasha J. McIntyre, Kelly Morrow, Glenda V. Roberts, Dharshana Sabanayagam, Michael G. Shlipak, Rukshana Shroff, Navdeep Tangri, Teerawat Thanachayanont, Ifeoma Ulasi, Germaine Wong, Chih‐Wei Yang, Luxia Zhang, Karen A. Robinson, Lisa M Wilson, Renée F Wilson, Bertram L. Kasiske, Michael Cheung, Amy Earley, Paul E. Stevens, Elke Schäeffner
Abstract
DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving kidney replacement therapy. METHODS: The KDIGO CKD Guideline Work Group defined the scope of the guideline and determined topics for systematic review. An independent Evidence Review Team systematically reviewed the evidence and graded the certainty of evidence for each of the review topics. Latest searches of the English-language literature were done in July 2023. Final modification of the guideline was informed by a public review process during summer of 2023 involving registered stakeholders. RECOMMENDATIONS: The full guideline included 28 recommendations and 141 practice points. This synopsis focuses on the recommendations that have the greatest evidence. Practice points reflect the expert opinion of the group where evidence is not that strong. Recommendations include greater emphasis on cystatin C for assessment of glomerular filtration rate, point-of-care testing in remote areas, a shift to an individualized risk-based approach to predict kidney failure, sodium-glucose cotransporter-2 inhibitors for some patients with CKD with and without diabetes, and statin use for adults older than 50 years and CKD. Together the recommendations and practice points provide guidance for how to evaluate and manage persons with CKD.